Life Sciences

  • June 18, 2026

    Fertility Chain Beats Suit Alleging Bogus Embryo Test Claims

    A fertility clinic chain has defeated a proposed class action accusing it of deceptively marketing its preimplantation genetic testing, after a Colorado federal judge found none of the patients claimed their own tests were inaccurate or caused a miscarriage or failed pregnancy.

  • June 18, 2026

    Novo Nordisk Sued Over Data Hack Tied To Extortionist Group

    Novo Nordisk was hit with a proposed negligence class action in New Jersey federal court alleging the pharmaceutical giant failed to have adequate data security measures in place to protect sensitive personal health information of patients and employees from being exposed to a cybercriminal extortionist group.

  • June 18, 2026

    Once Dominated By Patent Claims, IP Suits Now More Diverse

    Intellectual property litigation has become more spread out among patents, trademarks and copyrights over the years, as artificial intelligence and e-commerce systems have been drivers of legal matters, according to a new report.

  • June 18, 2026

    Full Fed. Circ. Skips DePuy Bid To Redo Spine Patent Dispute

    The full Federal Circuit won't revisit a panel decision that gave new life to an inventor's suit accusing DePuy Synthes Cos. of infringing his spinal realignment method patents, letting stand the decision that faulted a lower court's handling of expert testimony in the case.

  • June 18, 2026

    RFK Jr. Urges 1st Circ. To Reinstate His Vaccine Advisers

    U.S. Health Secretary Robert F. Kennedy Jr. told the First Circuit a Boston federal judge's decision to freeze his vaccine committee appointments lacks a legal foundation and has left the government paralyzed when it comes to vaccine policy.

  • June 18, 2026

    DEA Picks Only Pot Foes To Join Rescheduling Hearings

    The U.S. Drug Enforcement Administration on Thursday announced its selection of interested parties to participate in upcoming administrative hearings on a proposal to reclassify marijuana to a less restrictive status, each of whom is understood to oppose marijuana rescheduling.

  • June 18, 2026

    Cannabis World Cheers Justices' Gun Rights Ruling

    Cannabis industry stakeholders on Thursday largely applauded the U.S. Supreme Court's unanimous decision finding that a ban on gun ownership for drug users is unconstitutional as applied to a person who regularly uses marijuana.

  • June 18, 2026

    Goodwin, Latham Lead Biotech Kardigan's $400M IPO

    Venture-backed Kardigan Inc., a biotechnology firm developing therapies for cardiovascular diseases, hit the public markets on Thursday after raising $400 million in its initial public offering.

  • June 18, 2026

    Gibson Dunn Hires Ropes & Gray Health Regulatory Atty In DC

    Gibson Dunn & Crutcher LLP has hired a former Ropes & Gray LLP partner who works on a myriad of health regulatory and drug pricing matters, advising pharmaceutical manufacturers, investors and other entities on those issues, the firm announced Thursday.

  • June 18, 2026

    Patent Claims On Novartis Unit Drug Invalid, Del. Judge Says

    A Delaware federal judge has cleared radiopharmaceutical companies of allegations they infringed claims in various patents owned by a French unit of Novartis after finding that all of those claims were invalid.

  • June 18, 2026

    Pharma Co. Says Machine Breakdown Triggered Coverage

    A pharmaceutical company said its insurers improperly denied coverage to fix an eye dropper bottle filling machine, arguing the machine's breakdown caused extensive interruption to business activities that would trigger the policy, according to a complaint removed to California federal court Wednesday.

  • June 18, 2026

    High Court Bars Federal Review Of State Court Appeals

    The U.S. Supreme Court ruled Thursday that a legal doctrine designed to curtail duplicative litigation prevents parties who lose in state court from appealing in federal district court even if the state case is still pending.

  • June 18, 2026

    Justices Allow Gun Rights For Marijuana User

    U.S. Supreme Court justices ruled Thursday that the federal government cannot bar a drug user from owning guns, saying that the prosecution of a Texas man accused of owning a gun while being a marijuana user was inconsistent with the Second Amendment right to bear arms.

  • June 17, 2026

    Eli Lilly Urges Full Fed. Circ. To Scrap Teva's $177M IP Win

    Eli Lilly & Co. urged the full Federal Circuit Wednesday to review a panel ruling that upheld Teva's $177 million jury verdict on headache drug patents, arguing that the panel's decision runs afoul of the justices' Amgen holding and "opens a truck-sized hole in enablement and written description law."

  • June 17, 2026

    Hikma Ruling Raises Patent Pleading Bar Beyond Drug Cases

    The U.S. Supreme Court's decision this month that shut down a patent suit against Hikma Pharmaceuticals USA over a drug using a so-called skinny label could also make it more challenging to plead induced infringement in cases involving other technologies, attorneys say.

  • June 17, 2026

    Grocery Chain Says Aon Put $40M In Opioid Coverage At Risk

    Supermarket chain Giant Eagle on Wednesday hit insurance brokerage firm Aon with claims in Pennsylvania federal court that it jeopardized $40 million in coverage allegedly owed to the chain for settlement and defense costs in opioid litigation.

  • June 17, 2026

    Sen. Committee Clears Drug Disclosure, Biosimilar Bills

    The U.S. Senate Committee on Health, Education, Labor and Pensions on Wednesday cleared two bills for full Senate review, tackling the gap between health and patent oversight agencies, and the need for more interchangeable biosimilars.

  • June 17, 2026

    ITC, Masimo Tell Full Fed. Circ. To Skip Apple Watch Review

    Masimo Corp. and the U.S. International Trade Commission have pushed back on Apple's request for full Federal Circuit rehearing of a panel decision finding an older version of the Apple Watch infringes Masimo's patents, saying Wednesday the case isn't exceptional enough for such scrutiny.

  • June 17, 2026

    Embecta Investor Suit Says Pen Needle Weakness Was Hidden

    Medical device company Embecta Corp. and two of its executives were hit with a proposed class action Wednesday, alleging they misled investors about the sales performance of the company's pen needles, which are often used by patients with diabetes.

  • June 17, 2026

    Del. Court Invalidates Patent Claims In Bioscience Co. Row

    A federal magistrate judge in Delaware on Wednesday found that claims in three molecular labeling patents held by Parse Biosciences Inc. were invalid, months after he found that they weren't infringed by Scale Biosciences Inc.

  • June 17, 2026

    Fed. Circ. Affirms No Block On Stryker Spine Device In IP Fight

    The Federal Circuit on Wednesday agreed with a lower court decision rejecting Boston Scientific Corp.'s request to temporarily block Stryker Corp. from launching a back pain device, saying Stryker made a good enough case that it didn't cause physicians to infringe a patent on the treatment.

  • June 17, 2026

    Glenmark Pharma Beats Suit Over Recalled Cholesterol Drugs

    A New Jersey federal judge Wednesday tossed a proposed class action that accused drugmaker Glenmark Pharmaceuticals of falsely representing that its statin cholesterol drugs were safe and effective despite a recall over its manufacturing practices, saying plaintiff consumers' lack of actual economic or physical injury meant they couldn't sue.

  • June 17, 2026

    Syngenta, Chevron Bids To Move Paraquat Cases Opposed

    Plaintiffs alleging they developed Parkinson's disease from an herbicide asked a Philadelphia judge to block bids by Syngenta and Chevron to move the cases out of the city's mass tort system, arguing that the companies already tried that and failed.

  • June 17, 2026

    HHS Urges DC Court To Toss AbbVie 340B Audit Challenge

    A D.C. federal court should toss a suit by AbbVie challenging the U.S. Department of Health and Human Services' interpretation of who qualifies as a "patient" for audits under the federal 340B drug discount program, HHS said in a motion, arguing the court lacks jurisdiction.

  • June 16, 2026

    Sanofi Sued Over Qunol CoQ10 'Superior Absorption' Claims

    Sanofi-Aventis US deceives customers into believing its Qunol liquid CoQ10 supplements have "superior absorption" advantages compared to regular CoQ10 products despite scientific testing that shows otherwise and prior legal action that barred it from making similar efficacy claims, alleges a proposed class action filed Monday in New Jersey federal court.

Expert Analysis

  • High Court's Hikma Decision Reshapes 'Skinny Label' Suits

    Author Photo

    The U.S. Supreme Court's decision in Hikma v. Amarin marks a significant victory for generic drug manufacturers, but rather than putting an end to so-called skinny label inducement claims, it narrows and refocuses them, say attorneys at Sterne Kessler.

  • Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo

    Author Photo

    Virginia Gov. Abigail Spanberger's recent veto of legislation that would have established a regulated retail cannabis framework halts momentum built by the General Assembly, but it also sends important signals about what a future regulatory framework must address to survive, says Charles Slemp at Cozen.

  • Checking For AI Errors Is Now A Two-Way Street

    Author Photo

    A handful of recent federal and state cases demonstrate the importance of checking for errors generated by artificial intelligence not only in your own court submissions, but also your opponent's, as well as when catching opposing counsel's AI mistakes could result in an award for attorney fees, says Tamara Barago at Hollingsworth.

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

  • Why IPR Slowdown Has Not Led To More Patent Litigation

    Author Photo

    Despite sustained strength in patent application filings and a decline in inter partes review and post-grant review, 2026 has not seen the anticipated surge in patent litigation in district courts and at the U.S. International Trade Commission, potentially due to four reasons, say attorneys at Sterne Kessler.

  • 5 Things Associates Must Ask About Their Firm's Merger Plan

    Author Photo

    The associates who navigate law firm mergers best ask the right questions early, such as inquiring about partners' plans, to assess how the merger could affect their workflow and career path, says Jackie Bokser-LeFebvre at Major Lindsey.

  • Brain Computer Interfaces Boot Up Multipronged Legal Issues

    Author Photo

    As neurotechnology companies begin to conduct human clinical trials for brain computer interfaces, attorneys should prepare for legal ramifications across a broad range of practice areas, including intellectual property, privacy and product liability, say attorneys at ArentFox Schiff.

  • Turning To The Courts When PBM Reform Falls Short

    Author Photo

    The effectiveness of state laws intended to regulate pharmacy benefit managers remains uncertain, but litigation — utilizing tried-and-true theories like breach of contract and fair dealing — offers another mechanism through which stakeholders may seek relief from PBMs, say attorneys at Reed Smith.

  • 2 'Rocket Dockets' And The Rules That Propel Them

    Author Photo

    The fastest civil trial courts in the country are currently in the Eastern District of Virginia and the Southern District of Florida, and their chief judges provide insights into the court rules that keep them ahead, says Robert Tata at Hunton.

  • Calif. Ruling Lowers Bar For Health Data Breach Claims

    Author Photo

    The California Supreme Court's ruling in J.M. v. Illuminate Education offers protection for non-healthcare companies that maintain health-related data but also adopts a new and more plaintiff-favorable standard for breach of confidentiality that companies maintaining any health-related data should address, say attorneys at Cooley.

  • Teva Ruling Offers Patentees New Support For Genus Claims

    Author Photo

    The Federal Circuit's recent decision in Teva v. Eli Lilly, finding that the Teva patents at issue are not invalid, offers an interesting counterexample against the recent trend of courts invalidating patents claiming a broad, functionally defined class of compounds, say attorneys at Cooley.

  • Your Next Litigation Hold Should Cover AI Chat Logs

    Author Photo

    The Delaware Chancery Court’s recent decision in Fortis Advisors v. Krafton to treat a CEO’s artificial intelligence chats as substantive evidence is being read as a discovery warning to litigators, but there is a second duty-to-preserve lesson that is especially pertinent to in-house counsel, say attorneys at Faegre Drinker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.